

Contains Nonbinding Recommendations
Draft Guidance on Delavirdine Mesylate

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Delavirdine Mesylate

Form/Route: Tablets/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
Design: Single-dose, two-treatment, two-period crossover *in-vivo*
Strength: 200 mg
Subjects: Normal healthy males and females, general population. Females should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.

2. Type of study: Fed
Design: Single-dose, two-treatment, two-period crossover *in-vivo*
Strength: 200 mg
Subjects: Normal healthy males and females, general population. Females should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.

Analytes to measure (in appropriate biological fluid): Delavirdine in plasma

Bioequivalence based on (90% CI): Delavirdine

Waiver request of *in-vivo* testing: 100 mg based on (i) acceptable bioequivalence studies on the 200 mg strength, (ii) proportional similarity of the 100 mg formulation to the 200 mg strength, and (iii) acceptable *in-vitro* dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.fda.gov/cder/ogd/index.htm>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.